Collecting duct carcinoma
MONDO:0005220A carcinoma that arises from epithelial cells of the collecting duct of renal tubule
Also known as: BDC, Bellini carcinoma, Bellini duct carcinoma, CDC, cDC, carcinoma of collecting duct of renal tubule, carcinoma of collecting ducts of Bellini, carcinoma of kidney collecting duct
2783 clinical trials for this condition and its sub-types, 17 tagged with Collecting duct carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
Promising new therapy targets rare, aggressive cancers
Disease control OngoingThis study tests whether the drug ubamatamab, alone or with cemiplimab, can help control rare cancers like renal medullary carcinoma and epithelioid sarcoma. About 40 adults with advanced or metastatic disease will receive the treatment to check safety and effectiveness. The goal…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Promising combo aims to ease bone pain in advanced kidney cancer
Disease control OngoingThis study tests whether adding a radioactive drug (radium-223) to standard treatment (cabozantinib) helps people with advanced kidney cancer that has spread to the bones. About 134 participants will receive either the combination or cabozantinib alone. The goal is to see if the …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Triple-Drug cocktail shows promise for rare kidney cancers
Disease control OngoingThis study tests whether combining three drugs (cabozantinib, nivolumab, and ipilimumab) can safely slow or shrink advanced kidney cancers that are not the common clear-cell type. About 60 adults with cancers like papillary or chromophobe RCC that have spread will receive the com…
Phase 2 • Sponsor: Bradley A. McGregor, MD • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New combo therapy targets rare childhood and adult cancers
Disease control OngoingThis study tests two immunotherapy drugs, tiragolumab and atezolizumab, in children and adults with rare cancers that have come back or not responded to treatment. These cancers lack certain genes (SMARCB1 or SMARCA4), making them hard to treat. The goal is to see if the drug com…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Experimental drug tazemetostat offered to patients with rare, aggressive tumors
Disease control Expanded access (ended)This expanded access program provides tazemetostat, a drug that blocks a protein called EZH2, to adults with serious or life-threatening solid tumors that have lost the INI1 or SMARCA4 protein. Eligible patients must have tried other treatments without success and cannot join a f…
Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New combo therapy targets rare, aggressive kidney cancer
Disease control OngoingThis study tests whether two immunotherapy drugs, nivolumab and relatlimab, can shrink or control a rare and aggressive kidney cancer called renal medullary carcinoma (RMC). The trial includes 30 adults whose cancer has spread or cannot be removed by surgery. The goal is to see h…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New combo shows promise for rare kidney cancers
Disease control OngoingThis study tests a new two-drug combination (cadonilimab plus axitinib) as a first treatment for people with advanced or spread kidney cancer of rare types. About 37 participants will receive the drugs until their disease gets worse or side effects become too severe. The goal is …
Phase 1/2 • Sponsor: Hao Zeng • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New combo shows promise for tough kidney cancers
Disease control OngoingThis study tests two drugs, nivolumab and cabozantinib, together in 60 people with advanced or metastatic non-clear cell kidney cancer. The goal is to see how well the combination shrinks tumors. Participants take cabozantinib daily and receive nivolumab infusions every two weeks…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC